On Sept. 30, 2024, Amneal Pharmaceuticals announced that it had launched CREXONT ^® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT ^® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. CREXONT is now broadly available at U.S. pharmacies.

Parkinson’s disease (PD) has become the fastest growing neurological disorder worldwide, with approximately 1 million people diagnosed in the U.S.